Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical

Remedi Therapeutics

1 Drug Candidate

Remedi Therapeutics is a private biotech company developing a novel oral DMT formulation combined with a best-in-class, ultra-selective monoamine oxidase A inhibitor (RIMA) to create a predictable, convenient ayahuasca-like therapeutic. Unlike traditional ayahuasca, which uses plant-sourced harmine with off-target effects, Remedi's proprietary RIMA avoids gastrointestinal distress, tremors, and hypertensive risk, enabling pharmaceutical-grade oral DMT delivery for neuropsychiatric conditions.

Drug Pipeline

1

DMT + RIMA Combination

DMT
Pre-clinical
Depressive DisordersAnxiety DisordersPTSD

Novel oral kit formulation pairing DMT with a proprietary ultra-selective MAO-A inhibitor (RIMA). Designed to replace injectable/inhaled DMT protocols with a convenient, repeatable oral administration system for multiple neuropsychiatric indications.

Quick Facts

Type
Private Biotech
Lead Stage
Pre-clinical
Website
Visit